Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Operating Expenses: 2017-2024

Historic Operating Expenses for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $814.9 million.

  • BridgeBio Pharma's Operating Expenses rose 36.72% to $265.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $963.7 million, marking a year-over-year increase of 26.44%. This contributed to the annual value of $814.9 million for FY2024, which is 32.14% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Operating Expenses of $814.9 million as of FY2024, which was up 32.14% from $616.7 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Operating Expenses registered a high of $814.9 million during FY2024, and its lowest value of $482.7 million during FY2020.
  • Its 3-year average for Operating Expenses is $673.8 million, with a median of $616.7 million in 2023.
  • Per our database at Business Quant, BridgeBio Pharma's Operating Expenses soared by 57.34% in 2020 and then dropped by 8.74% in 2022.
  • BridgeBio Pharma's Operating Expenses (Yearly) stood at $482.7 million in 2020, then soared by 33.89% to $646.3 million in 2021, then fell by 8.74% to $589.9 million in 2022, then increased by 4.55% to $616.7 million in 2023, then spiked by 32.14% to $814.9 million in 2024.